Posted inCardiology news Specialties
The Soleus Muscle: The Body’s Second Heart and Its Vital Role
Discover the fascinating role of the soleus muscle, often called the body's second heart, in promoting circulation and overall health.
Posted inClinical Updates Neurology news Specialties
Elevated Risk of Alzheimer’s Disease and Related Dementias in Transfeminine Adults: Insights from a Large Cohort Study
Recent data reveal that transfeminine adults experience significantly higher prevalence of Alzheimer's disease and related dementias compared to matched cisgender peers, independent of gender-affirming hormone therapy, highlighting urgent needs for targeted research and care strategies.
Posted inMedical News news Public Health Specialties
Understanding Legionnaires’ Disease: A Public Health Concern
Legionnaires’ disease is a severe lung infection caused by bacteria in contaminated water systems. Recent cases in NYC highlight the importance of prevention and management.
Posted inClinical Updates news Ophthalmology Specialties
Alcon’s Tryptyr: A New Neuromodulatory Approach for Rapid Dry Eye Relief
Alcon introduces Tryptyr, the first TRPM8 agonist eye drop, promising rapid tear production for dry eye disease. FDA-approved in May 2024 following robust phase 3 trials.
Posted inMedical News news Public Health Specialties
Declining Vaccination Rates Among US Kindergarteners: A Growing Public Health Concern
Vaccination rates for US kindergarteners have declined for the third consecutive year, raising public health concerns. Experts attribute this trend to increased vaccine hesitancy and misinformation.
Posted inClinical Updates news Ophthalmology Specialties
FDA Approves Once-Daily Vizz (Aceclidine Ophthalmic Solution 1.44%) for Presbyopia: Clinical Implications and Evidence Review
The FDA has approved Vizz, a once-daily aceclidine ophthalmic solution, for presbyopia in adults based on robust phase 3 data. The eye drop offers up to 10 hours of improved near vision with a favorable safety profile.
Oveporexton: A Promising Orexin Receptor 2 Agonist for Narcolepsy Type 1 – Results from a Phase 2 Randomized Trial
Oveporexton, an oral orexin receptor 2–selective agonist, demonstrated significant improvements in wakefulness and cataplexy in narcolepsy type 1 patients over 8 weeks, with manageable adverse events.
Posted inClinical Updates HIV/AIDS news Specialties
Advances in Second-Line Antiretroviral Therapy for Children with HIV in Africa: Insights from the CHAPAS-4 Trial
TAF–emtricitabine and dolutegravir-based regimens outperform standard options as second-line ART for African children with HIV, offering improved viral suppression and safety.
Comparative Efficacy and Safety of Tolebrutinib in Multiple Sclerosis: Insights from Recent Phase 3 Trials
Tolebrutinib reduced disability progression in nonrelapsing secondary progressive MS but did not surpass teriflunomide in reducing relapse rates in relapsing MS. Safety signals include elevated liver enzymes and minor bleeding risks.
Posted inClinical Updates news Respiratory Specialties
Sotatercept in High-Risk Pulmonary Arterial Hypertension: A Landmark Advance in Patient Outcomes
Sotatercept significantly reduces the risk of death, lung transplantation, or hospitalization in high-risk pulmonary arterial hypertension patients, marking a major advance in the management of this life-threatening disease.
Posted inClinical Updates news Rheumatology Specialties
Upadacitinib and Janus Kinase Inhibitors in Giant-Cell Arteritis: Clinical Trial and Real-World Evidence
Upadacitinib at 15 mg with a 26-week glucocorticoid taper shows superior efficacy and comparable safety to placebo in giant-cell arteritis. Real-world data suggest JAK inhibitors, including upadacitinib, may benefit relapsing cases unresponsive to conventional therapies.
Posted inClinical Updates news Respiratory Specialties
Navigational Bronchoscopy Versus Transthoracic Needle Biopsy for Peripheral Lung Nodules: New Evidence from the VERITAS Trial
Navigational bronchoscopy offers noninferior diagnostic accuracy to transthoracic needle biopsy for peripheral pulmonary nodules, with notably fewer pneumothorax complications.
Posted inClinical Updates news Oncology Specialties
Regional Nodal Irradiation After Neoadjuvant Chemotherapy: Is Omission Safe for Breast Cancer Patients with ypN0 Status?
A landmark trial shows that omitting regional nodal irradiation after neoadjuvant chemotherapy in breast cancer patients with ypN0 status does not compromise recurrence or survival outcomes.
Trimethoprim–Sulfamethoxazole in Pregnancy: No Impact on Birth Weight in a Zimbabwean RCT
A large randomized trial in Zimbabwe found that trimethoprim–sulfamethoxazole prophylaxis during pregnancy did not significantly increase birth weight or reduce adverse outcomes.
Durable Efficacy and Long-term Safety of AAV Gene Therapy in Severe Hemophilia B: 13-Year Follow-up Results
A single AAV gene therapy infusion for severe hemophilia B led to sustained factor IX expression, substantial reduction in bleeding and factor use, and no late safety concerns over 13 years.
Posted inClinical Updates news Respiratory Specialties
Nerandomilast for Idiopathic and Progressive Pulmonary Fibrosis: Phase 3 Trial Insights
Phase 3 trials demonstrate that nerandomilast, a selective PDE4B inhibitor, significantly slows lung function decline in idiopathic and progressive pulmonary fibrosis over 52 weeks, with manageable safety profiles.
Interval Colorectal Cancer Risk and Outcomes after Positive FIT with Follow-Up Colonoscopy in Taiwan Screening Program
A Taiwanese cohort study reveals higher interval colorectal cancer incidence and mortality after follow-up colonoscopy for positive FIT compared to negative FIT, highlighting risk stratification and adenoma detection rate impact on outcomes.
Posted inClinical Updates Oncology Specialties
Bevacizumab and Erlotinib in Hereditary and Sporadic Papillary Kidney Cancer: New Therapeutic Prospects
A phase 2 study shows that bevacizumab and erlotinib combination therapy offers notable tumor responses and survival benefits in both hereditary and sporadic papillary renal-cell carcinoma, with manageable toxicity.
Corynebacterium diphtheriae Outbreak among Migrants in Europe: Clinical, Epidemiologic, and Microbiologic Insights
A multicountry outbreak of diphtheria among migrants in Europe raised concerns about cutaneous and respiratory disease, cross-border spread, and emerging antibiotic resistance. Genomic analysis revealed multiclonal transmission and resistance challenges for standard therapies.
Posted innews Oncology Specialties
Zongertinib: A Promising Oral Targeted Therapy for Previously Treated HER2-Mutant Non–Small-Cell Lung Cancer
Zongertinib shows high response rates and manageable toxicity in HER2-mutant NSCLC after prior treatments, offering a new oral therapy option.
